drugset
drugset / Trial / NCT05428930

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

NCT05428930 ↗

Phase 1 Completed 30 enrolled CKD Bio Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501B in Glabellar lines.

Timeline

Start
2022-06-22
Primary completion
2022-10-25
Completion
2022-10-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 50 iu Intramuscular
Subject CKDB-501B Unknown — Intramuscular

Indications

No indication recorded.